The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

Nicola Vannini, Girieca Lorusso, Rosaria Cammarota, Massimo Barberis, Douglas M. Noonan, Michael B. Sporn, Adriana Albini

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

We show that the synthetic oleanane triterpenoid, CDDO-methyl ester (CDDO-Me; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo. The potency of CDDO-Me is particularly strikingwhen dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-α in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body weight. If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis. CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required. We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker. Several known individual molecular targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-κB signaling, signal transducers and activators of transcription signaling, and transformingg rowth factor-β signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2. However, the particularly potent antiangiogenic activity seen in vivo in the present experiments suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of molecular and cellular targets, rather than at a single molecular locus or in a single-cell type.

Original languageEnglish
Pages (from-to)3139-3146
Number of pages8
JournalMolecular Cancer Therapeutics
Volume6
Issue number12
DOIs
Publication statusPublished - Dec 1 2007

Fingerprint

Angiogenesis Inhibitors
Porifera
oleanane
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate
Kaposi's Sarcoma
Transducers
Morphogenesis
Heterografts
Vascular Endothelial Growth Factor A
Transcription Factors
Endothelial Cells
Cell Culture Techniques
Tumor Necrosis Factor-alpha
Body Weight

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. / Vannini, Nicola; Lorusso, Girieca; Cammarota, Rosaria; Barberis, Massimo; Noonan, Douglas M.; Sporn, Michael B.; Albini, Adriana.

In: Molecular Cancer Therapeutics, Vol. 6, No. 12, 01.12.2007, p. 3139-3146.

Research output: Contribution to journalArticle

Vannini, Nicola ; Lorusso, Girieca ; Cammarota, Rosaria ; Barberis, Massimo ; Noonan, Douglas M. ; Sporn, Michael B. ; Albini, Adriana. / The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 12. pp. 3139-3146.
@article{fd754b4b790c4cc4b5d8f893f9139c39,
title = "The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent",
abstract = "We show that the synthetic oleanane triterpenoid, CDDO-methyl ester (CDDO-Me; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo. The potency of CDDO-Me is particularly strikingwhen dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-α in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body weight. If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis. CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required. We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker. Several known individual molecular targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-κB signaling, signal transducers and activators of transcription signaling, and transformingg rowth factor-β signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2. However, the particularly potent antiangiogenic activity seen in vivo in the present experiments suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of molecular and cellular targets, rather than at a single molecular locus or in a single-cell type.",
author = "Nicola Vannini and Girieca Lorusso and Rosaria Cammarota and Massimo Barberis and Noonan, {Douglas M.} and Sporn, {Michael B.} and Adriana Albini",
year = "2007",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-07-0451",
language = "English",
volume = "6",
pages = "3139--3146",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

AU - Vannini, Nicola

AU - Lorusso, Girieca

AU - Cammarota, Rosaria

AU - Barberis, Massimo

AU - Noonan, Douglas M.

AU - Sporn, Michael B.

AU - Albini, Adriana

PY - 2007/12/1

Y1 - 2007/12/1

N2 - We show that the synthetic oleanane triterpenoid, CDDO-methyl ester (CDDO-Me; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo. The potency of CDDO-Me is particularly strikingwhen dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-α in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body weight. If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis. CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required. We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker. Several known individual molecular targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-κB signaling, signal transducers and activators of transcription signaling, and transformingg rowth factor-β signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2. However, the particularly potent antiangiogenic activity seen in vivo in the present experiments suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of molecular and cellular targets, rather than at a single molecular locus or in a single-cell type.

AB - We show that the synthetic oleanane triterpenoid, CDDO-methyl ester (CDDO-Me; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo. The potency of CDDO-Me is particularly strikingwhen dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-α in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body weight. If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis. CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required. We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker. Several known individual molecular targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-κB signaling, signal transducers and activators of transcription signaling, and transformingg rowth factor-β signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2. However, the particularly potent antiangiogenic activity seen in vivo in the present experiments suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of molecular and cellular targets, rather than at a single molecular locus or in a single-cell type.

UR - http://www.scopus.com/inward/record.url?scp=37549054326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549054326&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-0451

DO - 10.1158/1535-7163.MCT-07-0451

M3 - Article

C2 - 18065492

AN - SCOPUS:37549054326

VL - 6

SP - 3139

EP - 3146

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -